2024
Efficacy and safety of implantable cardioverter-defibrillator implantation in the elderly—The I-70 Study: A randomized clinical trial
Singh S, Wininger M, Raitt M, Adabag S, Moore H, Rottman J, Scrymgeour A, Zhang J, Zheng K, Guarino P, Kyriakides T, Group I, Johnson G, Williams A, Beed A, MacMurdy K, Saavedra P. Efficacy and safety of implantable cardioverter-defibrillator implantation in the elderly—The I-70 Study: A randomized clinical trial. Heart Rhythm O2 2024, 5: 365-373. PMID: 38984364, PMCID: PMC11228113, DOI: 10.1016/j.hroo.2024.04.010.Peer-Reviewed Original ResearchImplantable cardioverter defibrillatorParticipant follow-upPatient treatment preferencesICD implantationFollow-upTarget sample sizeAll-cause hospitalizationsPrimary prevention ICD implantationMonths of follow-upImplantable cardioverter defibrillator therapySafety of implantable cardioverter defibrillatorsImplantable cardioverter defibrillator implantationOptimal medical therapyRate of sudden deathTreatment preferencesImplantable cardioverter defibrillator shocksSafety of ICD implantationConfidence intervalsStudy protocolMedical therapyParticipantsProlonging lifePatientsSudden deathCardioverter defibrillator
2022
Effect of preservation of antegrade hypogastric flow on development of claudication following aortoiliac aneurysm repair
Bennett K, Hurley L, Kyriakides T, Yi J, Freischlag J, Matsumura J, Group O. Effect of preservation of antegrade hypogastric flow on development of claudication following aortoiliac aneurysm repair. Journal Of Vascular Surgery 2022, 77: 1070-1076. PMID: 36565778, DOI: 10.1016/j.jvs.2022.12.022.Peer-Reviewed Original ResearchConceptsAortoiliac aneurysm repairDevelopment of claudicationButtock claudicationHypogastric flowClaudication symptomsHypogastric perfusionAneurysm repairArterial flowChronic obstructive pulmonary diseaseBilateral buttock claudicationPreoperative activity levelObstructive pulmonary diseaseBody mass indexIntervention-related changesOVER trialPulmonary diseaseStudy armsMass indexArterial perfusionClaudicationTrial investigatorsAnatomic levelTrial participantsTheoretical riskPatientsFacilitating future implementation and translation to clinical practice: The Implementation Planning Assessment Tool for clinical trials
Kowalski C, Kawentel L, Kyriakides T, Davis L, Bowersox N, Kilbourne A, Huang G, Nevedal A. Facilitating future implementation and translation to clinical practice: The Implementation Planning Assessment Tool for clinical trials. Journal Of Clinical And Translational Science 2022, 6: e131. PMID: 36590355, PMCID: PMC9794955, DOI: 10.1017/cts.2022.467.Peer-Reviewed Original ResearchClinical trialsVeterans Health Administration OfficePost-trial implementationRoutine care settingsClinical research programCooperative Studies ProgramImplementation science principlesAssessment toolCare settingsTrial completionClinical trialistsClinical practiceEffective interventionsTrial resultsInterventionImplementation scienceResearch protocolTrialsOne-fifthRigorous data collectionOverwhelming naturePatientsTrialists
2019
Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection
Ma R, Jung TH, Peduzzi PN, Brown ST, Kyriakides TC. Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2019, 18: 2325958219849101. PMID: 31272313, PMCID: PMC6748500, DOI: 10.1177/2325958219849101.Peer-Reviewed Original ResearchConceptsDrug changesCox proportional hazards regression modelKaplan-Meier survival techniqueMultidrug-resistant HIV infectionProportional hazards regression modelsAdvanced-stage AIDSDrug regimen changesSurvival of patientsHazards regression modelsAntiretroviral clinical trialsClinical biomarker dataCause mortalityMedication changesARV regimenHIV infectionImproved survivalRegimen changeClinical outcomesNonclinical reasonsClinical trialsBiomarker changesTreatment historyMultidrug resistanceTherapy strategiesPatients
2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2017
Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
Neocleous V, Fanis P, Toumba M, Phedonos AAP, Picolos M, Andreou E, Kyriakides TC, Tanteles GA, Shammas C, Phylactou LA, Skordis N. Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia. International Journal Of Endocrinology 2017, 2017: 8984365. PMID: 28487735, PMCID: PMC5405599, DOI: 10.1155/2017/8984365.Peer-Reviewed Original ResearchHeterozygous patientsNonclassic congenital adrenal hyperplasiaCategory of patientsCongenital adrenal hyperplasiaClinical hyperandrogenismHydroxyprogesterone levelsPhenotype-genotype correlationAdrenal hyperplasiaHigh riskAppropriate managementPatientsMild formFemale childrenHeterozygous mutationsHyperandrogenismSevere mutationsCYP21A2 geneHeterozygous femalesIdentification of variantsPresent studyFemalesRiskMutationsHyperandrogenaemiaHyperplasia
2016
Retrospective Case Control Study of the Incidence, Laterality, and Risk Factors of Ureteral Injuries in Patients Undergoing Hysterectomy
Stoltzman M, Kashani S, Kyriakides T. Retrospective Case Control Study of the Incidence, Laterality, and Risk Factors of Ureteral Injuries in Patients Undergoing Hysterectomy. Journal Of Minimally Invasive Gynecology 2016, 23: s63. DOI: 10.1016/j.jmig.2016.08.160.Peer-Reviewed Original Research
2015
A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study)
Frank C, Kyriakides T, Omar A, Friedland G, Andrews L, Melbourne K, Kozal M. A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study). Open Forum Infectious Diseases 2015, 2: 1082. DOI: 10.1093/ofid/ofv133.795.Peer-Reviewed Original ResearchElevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress
Koutsoulidou A, Kyriakides TC, Papadimas GK, Christou Y, Kararizou E, Papanicolaou EZ, Phylactou LA. Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress. PLOS ONE 2015, 10: e0125341. PMID: 25915631, PMCID: PMC4411125, DOI: 10.1371/journal.pone.0125341.Peer-Reviewed Original ResearchConceptsDM1 patientsMuscle-specific miRNAsMuscle wastingNatural historySensitive blood biomarkersPotential future therapiesDisease natural historyMyotonic dystrophy patientsAdult-onset muscular dystrophyMyotonic dystrophy type 1Useful molecular biomarkersParticipant seraSerum levelsMuscle weaknessBlood biomarkersClinical conditionsMuscle atrophyFuture therapiesPatientsPotential biomarkersDystrophy patientsMiR-133aType 1Progressive muscleMolecular biomarkers
2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 160-166. PMID: 20130473, DOI: 10.1097/qai.0b013e3181cbd235.Peer-Reviewed Original ResearchConceptsTreatment-naive populationTreatment-experienced patientsCD mutationsTreatment-experienced populationsHIV viral loadConnection domainConnection domain mutationsOPTIMA trialVirologic outcomesVirologic responseARV regimenARV therapyViral loadAntiretroviral drugsAntiretroviral trialsUnivariate analysisDiminished responseFrequency of mutationsMultivariate analysisPatientsReduced susceptibilityA371VDomain mutationsResistance phenotypeTrials
2009
Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST. Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 631-639. PMID: 19430303, DOI: 10.1097/qai.0b013e3181a4f00d.Peer-Reviewed Original ResearchConceptsSerious adverse eventsLate-stage HIV/AIDSAdvanced HIV/AIDSHIV/AIDSAdverse eventsMedical Outcomes Study HIV Health SurveyMental health summary scoresEffect of ADEMultidrug-resistant HIVHealth-related qualityHealth summary scoresQuality of lifePatients' HRQOLMultivariate linear regression modelRegular followHRQOL measuresTreatment strategiesEQ-5DHealth SurveyHRQoLImmune diseasesSummary scoresPatientsStudy sample populationAIDS
2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar time
2001
Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther supportDevelopment and Application of a Genotypic AZT Resistance Assay
Kyriakides T, Heimer R. Development and Application of a Genotypic AZT Resistance Assay. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211-220. DOI: 10.1097/00126334-200111010-00002.Peer-Reviewed Original ResearchViral loadCD4 countAZT resistanceResistance indexResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentResistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityReaction assaysCountAssaysFurther supportIndexAntiretroviralsHIV